Imeglimin

Imeglimin (brand name Twymeeg) is an oral anti-diabetic medication.[1][2] It was approved for use in Japan in June 2021.[3]

Imeglimin
Clinical data
Trade namesTwymeeg
ATC code
Legal status
Legal status
  • Rx-only in Japan
Identifiers
IUPAC name
  • (2S)-N6,N6,2-Trimethyl-1,2-dihydro-1,3,5-triazine-4,6-diamine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC6H13N5
Molar mass155.205 g·mol−1
3D model (JSmol)
SMILES
  • C[C@H]1NC(=NC(=N1)N)N(C)C
InChI
  • InChI=1S/C6H13N5/c1-4-8-5(7)10-6(9-4)11(2)3/h4H,1-3H3,(H3,7,8,9,10)/t4-/m1/s1
  • Key:GFICWFZTBXUVIG-SCSAIBSYSA-N

It is an oxidative phosphorylation blocker that acts to inhibit hepatic gluconeogenesis, increase muscle glucose uptake, and restore normal insulin secretion. It is the first approved drug of this class of anti-diabetic medication.

References
  1. Vuylsteke V, Chastain LM, Maggu GA, Brown C (September 2015). "Imeglimin: A Potential New Multi-Target Drug for Type 2 Diabetes". Drugs in R&D. 15 (3): 227–32. doi:10.1007/s40268-015-0099-3. PMC 4561051. PMID 26254210.
  2. Dubourg J, Fouqueray P, Thang C, Grouin JM, Ueki K (April 2021). "Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial". Diabetes Care. 44 (4): 952–959. doi:10.2337/dc20-0763. PMID 33574125.
  3. Poxel SA (June 23, 2021). "Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan" (Press release).
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.